Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2013 by Dana-Farber Cancer Institute.
Recruitment status was  Active, not recruiting
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Synta Pharmaceuticals Corp.
Information provided by (Responsible Party):
Leena Gandhi, MD, PhD, Dana-Farber Cancer Institute Identifier:
First received: July 29, 2010
Last updated: February 22, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)